Categories AlphaGraphs, Earnings, LATEST, Technology
Trxade Health (MEDS) reports 6% growth in Q1 revenue; loss widens
Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a wider net loss for the first quarter of 2022 despite a 6% increase in revenues. The top-line also beat analysts’ estimates.
First-quarter revenues increased 6% year-over-year to $3.2 million and came in above analysts’ estimates. The company added 339 registered members during the three-month period.
Trxade reported a net loss of $1 million or $0.12 per share for the first quarter, compared to a loss of $0.7 million or $0.08 per share in the year-ago quarter. The bottom line missed analysts’ estimates.
Check this space to read management/analysts’ comments on Trxade’s Q1 2022 results
Shares of Trxade closed Monday’s trading lower. The stock has lost about 41% so far this year.
Prior Performance
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
